The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Calvin J Gordon, Egor P Tchesnokov, Joy Y Feng, Danielle P Porter, Matthias Götte, Calvin J Gordon, Egor P Tchesnokov, Joy Y Feng, Danielle P Porter, Matthias Götte

Abstract

Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.

Keywords: Ebola virus (EBOV); Middle East respiratory syndrome coronavirus (MERS–CoV); RNA chain termination; RNA-dependent RNA polymerase (RdRp); SARS–CoV-2; antiviral drug; coronavirus; drug development; enzyme inhibitor; nucleoside/nucleotide analog; plus-stranded RNA virus; positive-sense RNA virus; remdesivir; viral polymerase; viral replicase.

Conflict of interest statement

M. G. has previously received funding from Gilead Sciences in support for the study of EBOV RdRp inhibition by RDV

© 2020 Gordon et al.

Figures

Figure 1.
Figure 1.
Expression, purification, and characterization of the MERS RdRp complex.A, the construct contains nonstructural proteins nsp5, nsp7, nsp8, and nsp12. Red rectangles indicate original nsp5 protease cleavage sites. His8 and Strep indicate the locations of histidine and strep tags, respectively. B, a snapshot of a sequence alignment (T-Coffee) of representative RdRp enzymes from positive-sense RNA genome viruses illustrating sequence conservation within RdRp motif C.C, SDS-PAGE migration pattern of the purified enzyme preparations stained with Coomassie Brilliant Blue G-250 dye. Proteins migrating at ∼100 and ∼25 kDa contain nsp12 and nsp8, respectively. D, RNA synthesis on a short model primer/template substrate. Template and primer were both phosphorylated (p) at their 5′-ends. Gindicates incorporation of the radiolabeled nucleotide opposite template position 5. RNA synthesis was monitored with the purified MERS RdRp complex wt (motif C = SDD) and active-site mutant (motif C = SNN) in the presence of NTP combinations designed to generate specific products. Lanes m illustrate the migration pattern of the radiolabeled 4-nucleotide-long primer. HCV, hepatitis C virus;NoV, norovirus; PoV, poliovirus.
Figure 2.
Figure 2.
Patterns of inhibition of RNA synthesis with RDV-TP.A, RNA primer/template substrates used to test multiple (left panel) or single (right panel) incorporations of RDV-TP.G indicates incorporation of the radiolabeled nucleotide opposite template position 5. i indicates incorporation site for the first (left panel) or the only (right panel) RDV-TP.Full length indicates the full-template length products of RNA synthesis. B, RDV-TP incorporation was monitored with purified EBOV and MERS RdRp complexes in the presence of the indicated combinations of NTPs and RDV-TP.
Figure 3.
Figure 3.
Competition between RDV-TP and ATP.A, the RNA primer/template substrate used in this assay is shownabove the gel. G indicates incorporation of the radiolabeled nucleotide opposite template position 5. Position iallows incorporation of ATP or RDV-TP. RNA synthesis was monitored with purified MERS RdRp complex in the presence of 0.02 μm ATP, CTP, and UTP mix and increasing concentrations of RDV-TP as indicated. B, graphic representation and IC50 determination fitting of quantified data fromA. The error bars represent standard deviation of the data within four independent experiments. C, graphic representation of the relationship between IC50 values for RDV-TP measured at different NTP concentrations. The average IC50 values for RDV-TP are shown above the corresponding bars. Theerror bars represent standard deviation of the data within at least three independent experiments.
Figure 4.
Figure 4.
Chemical structures of ATP and ATP analogs.

References

    1. Sheahan T. P., Sims A. C., Leist S. R., Schäfer A., Won J., Brown A. J., Montgomery S. A., Hogg A., Babusis D., Clarke M. O., Spahn J. E., Bauer L., Sellers S., Porter D., Feng J. Y., et al. (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon β against MERS–CoV. Nat. Commun. 11, 222 10.1038/s41467-019-13940-6
    1. Siegel D., Hui H. C., Doerffler E., Clarke M. O., Chun K., Zhang L., Neville S., Carra E., Lew W., Ross B., Wang Q., Wolfe L., Jordan R., Soloveva V., Knox J., et al. . (2017) Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J. Med. Chem. 60, 1648–1661 10.1021/acs.jmedchem.6b01594
    1. Lo M. K., Jordan R., Arvey A., Sudhamsu J., Shrivastava-Ranjan P., Hotard A. L., Flint M., McMullan L. K., Siegel D., Clarke M. O., Mackman R. L., Hui H. C., Perron M., Ray A. S., Cihlar T., et al. (2017) GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci. Rep. 7, 43395 10.1038/srep43395
    1. Warren T. K., Jordan R., Lo M. K., Ray A. S., Mackman R. L., Soloveva V., Siegel D., Perron M., Bannister R., Hui H. C., Larson N., Strickley R., Wells J., Stuthman K. S., Van Tongeren S. A., et al. . (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381–385 10.1038/nature17180
    1. Agostini M. L., Andres E. L., Sims A. C., Graham R. L., Sheahan T. P., Lu X., Smith E. C., Case J. B., Feng J. Y., Jordan R., Ray A. S., Cihlar T., Siegel D., Mackman R. L., Clarke M. O., et al. . (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9, e00221–18
    1. Brown A. J., Won J. J., Graham R. L., Dinnon K. H. 3rd, Sims A. C., Feng J. Y., Cihlar T., Denison M. R., Baric R. S., and Sheahan T. P. (2019) Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 169, 104541 10.1016/j.antiviral.2019.104541
    1. Jordan P. C., Liu C., Raynaud P., Lo M. K., Spiropoulou C. F., Symons J. A., Beigelman L., and Deval J. (2018) Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase. PLoS Pathog. 14, e1006889 10.1371/journal.ppat.1006889
    1. Tchesnokov E. P., Feng J. Y., Porter D. P., and Götte M. (2019) Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 11, E326
    1. Mühlberger E., Weik M., Volchkov V. E., Klenk H. D., and Becker S. (1999) Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73, 2333–2342 10.1128/JVI.73.3.2333-2342.1999
    1. Tchesnokov E. P., Raeisimakiani P., Ngure M., Marchant D., and Götte M. (2018) Recombinant RNA-dependent RNA polymerase complex of Ebola virus. Sci. Rep. 8, 3970 10.1038/s41598-018-22328-3
    1. Deval J., Hong J., Wang G., Taylor J., Smith L. K., Fung A., Stevens S. K., Liu H., Jin Z., Dyatkina N., Prhavc M., Stoycheva A. D., Serebryany V., Liu J., Smith D. B., et al. (2015) Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2′-fluoro-4′-chloromethyl-cytidine triphosphate. PLoS Pathog. 11
    1. Noton S. L., Deflubé L. R., Tremaglio C. Z., and Fearns R. (2012) The respiratory syncytial virus polymerase has multiple RNA synthesis activities at the promoter. PLoS Pathog. 8, e1002980 10.1371/journal.ppat.1002980
    1. Kirchdoerfer R. N., and Ward A. B. (2019) Structure of the SARS–CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat. Commun. 10, 2342 10.1038/s41467-019-10280-3
    1. Ferron F., Subissi L., Silveira De Morais A. T., Le N. T. T., Sevajol M., Gluais L., Decroly E., Vonrhein C., Bricogne G., Canard B., and Imbert I. (2018) Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc. Natl. Acad. Sci. U.S.A. 115, E162–E171 10.1073/pnas.1718806115
    1. Subissi L., Posthuma C. C., Collet A., Zevenhoven-Dobbe J. C., Gorbalenya A. E., Decroly E., Snijder E. J., Canard B., and Imbert I. (2014) One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc. Natl. Acad. Sci. U.S.A. 111, E3900–E3909 10.1073/pnas.1323705111
    1. Poch O., Sauvaget I., Delarue M., and Tordo N. (1989) Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8, 3867–3874 10.1002/j.1460-2075.1989.tb08565.x
    1. Imbert I., Guillemot J. C., Bourhis J. M., Bussetta C., Coutard B., Egloff M. P., Ferron F., Gorbalenya A. E., and Canard B. (2006) A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus. EMBO J. 25, 4933–4942 10.1038/sj.emboj.7601368
    1. Mulangu S., Dodd L. E., Davey R. T. Jr., Tshiani Mbaya O., Proschan M., Mukadi D., Lusakibanza Manzo M., Nzolo D., Tshomba Oloma A., Ibanda A., Ali R., Coulibaly S., Levine A. C., Grais R., Diaz J., et al. (2019) A randomized, controlled trial of Ebola virus disease therapeutics. New Engl. J. Med. 381, 2293–2303 10.1056/NEJMoa1910993
    1. Sheahan T. P., Sims A. C., Graham R. L., Menachery V. D., Gralinski L. E., Case J. B., Leist S. R., Pyrc K., Feng J. Y., Trantcheva I., Bannister R., Park Y., Babusis D., Clarke M. O., Mackman R. L., et al. . (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 10.1126/scitranslmed.aal3653
    1. de Wit E., Feldmann F., Cronin J., Jordan R., Okumura A., Thomas T., Scott D., Cihlar T., and Feldmann H. (2020) Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS–CoV infection. Proc. Natl. Acad. Sci. U.S.A. 201922083 10.1073/pnas.1922083117
    1. de Wilde A. H., Jochmans D., Posthuma C. C., Zevenhoven-Dobbe J. C., van Nieuwkoop S., Bestebroer T. M., van den Hoogen B. G., Neyts J., and Snijder E. J. (2014) Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother. 58, 4875–4884 10.1128/AAC.03011-14
    1. Arabi Y. M., Asiri A. Y., Assiri A. M., Aziz Jokhdar H. A., Alothman A., Balkhy H. H., AlJohani S., Al Harbi S., Kojan S., Al Jeraisy M., Deeb A. M., Memish Z. A., Ghazal S., Al Faraj S., Al-Hameed F., et al. . (2020) Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials 21, 8 10.1186/s13063-019-3846-x
    1. Tchesnokov E. P., Obikhod A., Schinazi R. F., and Götte M. (2008) Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J. Biol. Chem. 283, 34218–34228 10.1074/jbc.M806797200
    1. Dulin D., Arnold J. J., van Laar T., Oh H. S., Lee C., Perkins A. L., Harki D. A., Depken M., Cameron C. E., and Dekker N. H. (2017) Signatures of nucleotide analog incorporation by an RNA-dependent RNA polymerase revealed using high-throughput magnetic tweezers. Cell Reports 21, 1063–1076 10.1016/j.celrep.2017.10.005
    1. Berger I., Fitzgerald D. J., and Richmond T. J. (2004) Baculovirus expression system for heterologous multiprotein complexes. Nat. Biotechnol. 22, 1583–1587 10.1038/nbt1036
    1. Bieniossek C., Richmond T. J., and Berger I. (2008) MultiBac: multigene baculovirus-based eukaryotic protein complex production. Curr. Protoc. Protein Sci. Chapter 5, Unit 5.20 10.1002/0471140864.ps0520s51

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe